Compare Illumina, Inc. (ILMN) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JPMorgan Equity Premium Income ETF — how do they compare? Illumina, Inc. trades at $191.08 (market cap $29.12B), while JPMorgan Equity Premium Income ETF trades at $57.84. The key difference: Illumina, Inc. is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | JEPI | |
|---|---|---|
Market Cap | $29.12B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $205.10 | $59.88 |
52-Week Low | $91.00 | $55.29 |
Enterprise Value | $30.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
JEPI trades at $57.8, up 0.28% today, with a bullish technical signal driven by moving averages. The ETF focuses on generating income through covered calls, offering monthly dividends, but key valuation ratios are not publicly disclosed. Recent news highlights its popularity among retirees for yield, though some articles note underperformance versus peers.
Outlook is mixed: strong income appeal supports demand, but competition and potential tax inefficiencies pose risks. Investors should weigh the high yield against total return lag and market volatility exposure. The bullish technical trend may face resistance near current levels if overbought conditions persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
